Vivoryon Therapeutics Current Valuation vs. Shares Owned By Insiders

VVY Stock   1.96  0.04  2.00%   
Based on Vivoryon Therapeutics' profitability indicators, Vivoryon Therapeutics NV may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Vivoryon Therapeutics' ability to earn profits and add value for shareholders.
For Vivoryon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vivoryon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vivoryon Therapeutics NV utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vivoryon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vivoryon Therapeutics NV over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Vivoryon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivoryon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivoryon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vivoryon Therapeutics Shares Owned By Insiders vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vivoryon Therapeutics's current stock value. Our valuation model uses many indicators to compare Vivoryon Therapeutics value to that of its competitors to determine the firm's financial worth.
Vivoryon Therapeutics NV is rated first in current valuation category among its peers. It is rated first in shares owned by insiders category among its peers . The ratio of Current Valuation to Shares Owned By Insiders for Vivoryon Therapeutics NV is about  7,194,597 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vivoryon Therapeutics' earnings, one of the primary drivers of an investment's value.

Vivoryon Current Valuation vs. Competition

Vivoryon Therapeutics NV is rated first in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about 2.86 Billion. Vivoryon Therapeutics holds roughly 240.95 Million in current valuation claiming about 8% of stocks in Biotechnology industry.

Vivoryon Shares Owned By Insiders vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Vivoryon Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
240.95 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Vivoryon Therapeutics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
33.49 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Vivoryon Shares Owned By Insiders Comparison

Vivoryon Therapeutics is currently under evaluation in shares owned by insiders category among its peers.

Vivoryon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vivoryon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vivoryon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vivoryon Therapeutics' important profitability drivers and their relationship over time.

Use Vivoryon Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vivoryon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivoryon Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Vivoryon Therapeutics Pair Trading

Vivoryon Therapeutics NV Pair Trading Analysis

The ability to find closely correlated positions to Vivoryon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vivoryon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vivoryon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vivoryon Therapeutics NV to buy it.
The correlation of Vivoryon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vivoryon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vivoryon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vivoryon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Vivoryon Therapeutics position

In addition to having Vivoryon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run USD Crypto Fund Thematic Idea Now

USD Crypto Fund
USD Crypto Fund Theme
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vivoryon Stock Analysis

When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.